1-4 September 2019
- Jadel Kratz, Discovery Manager – session on open innovation
by Franco CH, Alcântara LM, Chatelain E, Freitas-Junior L, Borsoi Moraes C.
Tropical Medicine and Infectious Disease, May 2019
25-29 August 2019
San Diego, USA
- Poster presentation on drug discovery collaboration with students
The Telegraph [8 May 2019]
“How a Wikipedia for drug discovery is disrupting big pharma”
BioSpace [18 April 2019]
“BioSpace’s Global Biopharma Roundup”
BioCentury [17 April 2019]
“Atomwise unveils Chagas disease compounds from AIMS program”
12-15 May 2019
- Isabela Ribeiro, Head of Dynamic Portfolio Unit – presentation on clinical trials for Chagas disease
- Nick White, Chair DNDi SAC – presentation on the global situation in infectious diseases & drug discovery for infectious diseases
- Poster presentations on drug discovery projects for Chagas disease and leishmaniasis
11 April 2019
Rio de Janeiro, Brazil
- Jadel Kratz, Discovery Manager – moderator for a discussion on tuberculosis
Brazilian Society of Tropical Medicine [14 March 2019]
“Pandemic Response Box: Responding to a potential global medical emergency”
by Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, Wijnant GJ, Yardley V, Braillard S, Mowbray CE, Ioset JR, Croft SL.
International Journal for Parasitology: Drugs and Drug Resistance, February 2019
In Africa, results of a Phase III study on HIV/VL in Ethiopia showed high efficacy of a new combination therapy for co-infected patients, a Phase III study began to test new combination treatment for visceral leishmaniasis, and a Phase II study testing new treatments for PKDL started in Sudan. In Asia, the results of an infectivity study in Bangladesh confirmed that PKDL acts as a reservoir for leishmaniasis infection, with implications for elimination efforts across South Asia. In Latin America, the Brazilian Ministry of Health is reviewing its treatment policy to consider the adoption of AmBisome as the country’s first-line visceral leishmaniasis treatment.
A Phase II study of new benznidazole regimens was completed in 2018 with results coming in 2019. A Phase II study of fexinidazole, a new drug being tested for Chagas, completed patient recruitment in 2018. New diagnosis and treatment access projects were launched in Guatemala and Brazil, and the project in Colombia showed major increases in people tested in pilot areas.
Two Phase I studies in healthy volunteers for potentially macrofilaricidal drugs were successfully completed, for emodepside (Bayer) and the antibiotic TylAMac (AbbVie). Phase II studies are planned for sub-Saharan Africa.
Health Policy Watch [5 February 2019]
“New funding partnership to develop innovative drugs for leishmaniasis”
London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.
20-23 February 2019
- Presentation of the development of DNDI-0690, a new clinical candidate for visceral leishmaniasis
20-22 February 2019
- Presentation of a poster on drug discovery for leishmaniasis (Open Synthesis Project)